Literature DB >> 12441213

Endothelial function in sustained and white coat hypertension.

Sante D Pierdomenico1, Francesco Cipollone, Domenico Lapenna, Anna Bucci, Franco Cuccurullo, Andrea Mezzetti.   

Abstract

BACKGROUND: Endothelial dysfunction is a frequent finding in essential hypertension. The aim of this study was to assess endothelial function, by evaluating circulating nitric oxide metabolites, nitrate plus nitrite (NOx), and endothelium-dependent vasodilation (EDD), in white coat hypertension in comparison with sustained hypertension and normotension.
METHODS: We selected 22 sustained hypertensive, 22 white coat hypertensive, and 22 normotensive subjects matched for age, gender, body mass index, and occupation. Women were also matched for menopausal status. Subjects with smoking habit, dyslipidemia, and diabetes mellitus were excluded from the study. White coat hypertension was defined as clinical hypertension and daytime ambulatory blood pressure (BP) <135/85 mm Hg. Groups received for 2 days a low-nitrate diet before obtaining blood samples for laboratory measurements. The NOx levels were measured by using the Griess reagent after enzymatic conversion of all nitrate to nitrite. Subjects also underwent brachial artery study by ultrasonography to evaluate EDD and endothelium-independent vasodilation.
RESULTS: White coat hypertensive subjects had significantly higher levels of NOx than sustained hypertensive patients (30.8 +/- 12 v 22 +/- 8.5 micromol/L, P <.05) and significantly higher EDD (7.8% +/- 3.1% v 4.6% +/- 3.0%, P <.05). No significant difference was observed between white coat hypertensive and normotensive subjects regarding these parameters. Endothelium-independent vasodilation was not significantly different among sustained hypertensives, white coat hypertensives, and normotensives (18% +/- 4.2% v 18.3% +/- 3.9% v 18.6% +/- 4.8%, respectively, P = not significant).
CONCLUSIONS: Our data suggest that middle-aged white coat hypertensive subjects without other cardiovascular risk factors do not show endothelial dysfunction in contrast with sustained hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441213     DOI: 10.1016/s0895-7061(02)02993-x

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  Isolated office hypertension: association with target organ damage and cardiovascular risk indices.

Authors:  Nuri Kamel; Alptekin Gursoy; Osman Koseoglulari; Irem Dincer; Sevim Gullu
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

2.  Coronary flow reserve is preserved in white-coat hypertension.

Authors:  D Erdogan; H Gullu; M Caliskan; I Yildirim; D Tok; H Muderrisoglu
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

3.  White coat hypertension: addressing the 10 most important questions.

Authors:  Louis Kuritzky
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

Review 4.  Endothelial dysfunction: its role in hypertensive coronary disease.

Authors:  Islam Bolad; Patrice Delafontaine
Journal:  Curr Opin Cardiol       Date:  2005-07       Impact factor: 2.161

Review 5.  Closer look at white-coat hypertension.

Authors:  Nurver Turfaner Sipahioglu; Fikret Sipahioglu
Journal:  World J Methodol       Date:  2014-09-26

6.  Should white coat hypertension be treated?

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-09       Impact factor: 3.738

7.  Subclinical Organ Damage in White-Coat Hypertension: The Possible Role of Cystatin C.

Authors:  Emmanuel Androulakis; Nikolaos Papageorgiou; Eirini Lioudaki; Evaggelos Chatzistamatiou; Effimia Zacharia; Ioannis Kallikazaros; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-21       Impact factor: 3.738

8.  Diagnostic value and cost-benefit analysis of 24 hours ambulatory blood pressure monitoring in primary care in Portugal.

Authors:  Paulo Pessanha; Manuel Viana; Paula Ferreira; Susana Bertoquini; Jorge Polónia
Journal:  BMC Cardiovasc Disord       Date:  2013-08-12       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.